Abstract 246P
Background
To study the main causes of neglect of advanced cervical cancer (CC) in Uzbekistan based on the results of a survey of advanced stage cervical cancer patients. The questionnaire was analyzed in 3 directions: “patient delay”, “doctor delay”, “delay of treatment”.
Methods
200 patients with advanced cervical cancer were included in the analysis, including: IIA-B stage-17%; IIIA-B stage 80%; IVA stage - 3%. Descriptive analyses were provided with the WHO questionnaire, adopted for local use, which should explore the possible barriers of early detection of cervical cancer.
Results
In the questionnaire analysis, the following results were obtained in the direction of “doctor delay”: 1. Which doctor did you talk about the symptoms of the disease? General practioner - 8%, gynecologist - 90%, private doctor - 2%; 2. Prior to the establishment of diagnosis contacted doctor: once - 22%, twice - 29%, 3 times and more - 49%. 3. How many times did you have a doctor before starting chemotherapy: Never - 86%, 3 or more times 14%. 4. Some aspects of the treatment surprised patients, no one warned: yes-56%, no-54%; I can easily ask doctor about the disease: Yes-45%, no-55%. 5. Appeal to the doctors before the establishment of diagnosis: twice - 29%, 3 and more time - 49%; To which specialist did you first tell about the symptoms of the disease: Physician - 97%, nurse - 2%, healer - 1%. 6. How many times have been in doctor with relatives: Never -37%; once - 19%; twice - 24%; 3 and more times - 20%. 7. Where you underwent the necessary examinations: State clinic - 70%; private clinic - 30%.
Conclusions
The main reasons for the neglect of cervical cancer in the direction of “doctor delay” are: Weak awareness of general practitioners; Unsatisfactory in forming patients about the severity of the disease, inability to enter the patient's trust; Absence or low level of psychological support of patients; Problems of timely referral of patients to an oncologist; Problems of deontology in the chain: doctor-diagnosis-patient. Elimination of the above-mentioned main causes will lower the incidence and mortality from cervical cancer and improve treatment outcomes, preventing disability of women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nargiza Zakhirova.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract